Malaria: One Drug, Double Action

  • Author: Melania Tesio
  • Published: 03 April 2013
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Science Translational Medicine/American Association for the Advancement of Science (AAAS)
thumbnail image: Malaria: One Drug, Double Action

Malaria is a severe infection caused by the Plasmodium parasite. This disease is characterized by a first asymptomatic liver stage, during which the Plasmodium reproduces in hepatic cells, and a second symptomatic stage, during which the parasite replicates within blood cells. Nevertheless, most antimalaric treatments, such as the naphthoquinone atovaquone, target only the blood phase of the disease and they are not effective against drug resistant parasite strains.

Aaron Nielsen, Veterans Affair Medical Center, Portland, USA and colleagues demonstrated that a new drug, ELQ-300 (pictured), offers a way around these issues. The novel compound, a 4(1H)-quinolone bearing a diarylether side chain in the quinolone core, blocks both the blood and the liver stage infection and acts against atovaquone-resistant strains of Plasmodium Palciparum. ELQ-300, moreover, shows high metabolic activity and oral efficacy, thus representing a promising antimalarial drug.

Article Views: 2869

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from, please contact us first for permission. more

CONNECT: on Facebook on Twitter on YouTube on LinkedIn Sign up for our free newsletter

A product of ChemPubSoc Europe (16 European Chemical Societies)published by Wiley-VCH